RHYTHM PHARMACEUTICALS, INC. ($RYTM)
Filing Information
| Accession Number | 0001104659-26-014546 |
|---|---|
| Form Type | 4 |
| Filing Date | Feb 13, 2026 |
| Document Date | Feb 10, 2026 |
| Document | View SEC Filing |
Transactions
12
Total Shares
69,571
Total Value
$708,575.59
P&L
+inf% (+$5,465,625.00)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock | โ | Feb 10, 2026 | Sale | 1,913 | $102.66 | $196,379.78 | 123,624 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 10, 2026 | Sale | 700 | $103.68 | $72,573.69 | 122,924 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 10, 2026 | Sale | 100 | $104.76 | $10,476.00 | 122,824 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 11, 2026 | Sale | 2,266 | $98.37 | $222,906.42 | 120,558 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 11, 2026 | Sale | 400 | $99.44 | $39,774.72 | 120,158 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 11, 2026 | Sale | 100 | $100.85 | $10,085.27 | 120,058 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 12, 2026 | Sale | 292 | $96.26 | $28,108.71 | 119,766 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 12, 2026 | Sale | 400 | $97.67 | $39,068.52 | 119,366 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 12, 2026 | Sale | 800 | $98.99 | $79,192.48 | 118,566 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 12, 2026 | Sale | 100 | $100.10 | $10,010.00 | 118,466 | Direct | โ | View Details | |
Chief Financial Officer | Restricted Stock Units | Derivative | Feb 11, 2026 | Grant/Award | 25,000 | $0.00 | $0.00 | 25,000 | Direct | โ | View Details | |
Chief Financial Officer | Stock Options (Right to Buy) | Derivative | Feb 11, 2026 | Grant/Award | 37,500 | $0.00 | $0.00 | 37,500 | Direct | โ | View Details |